Skip to Main Content

Paper Details

Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
JAMA Netw Open
68
2021
ASCVD, Dyslipidemia, HDL-C, LDL-C, Patient, Persons, Statins, alcohol, atherosclerotic cardiovascular disease, cardiovascular, cholesterol, diabetes, dyslipidemia, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, participants, statin, triglycerides, women
Adult, Age Distribution, Aged, Cardiovascular Diseases, China, Cholesterol, LDL, Cross-Sectional Studies, Dyslipidemias, Female, Health Services Accessibility, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Prevalence, Primary Health Care
Author NameAffiliation
Yuan LuCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, Yale School of Medicine
Haibo ZhangNational Clinical Research Center for Cardiovascular Diseases, National Health Commission Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Jiapeng LuNational Clinical Research Center for Cardiovascular Diseases, National Health Commission Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Qinglan DingCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, Yale School of Medicine
Xinyue LiYale University
Xiaochen WangYale University
Dan-Qin SunYale University
Lingyi TanYale University
Lin MuCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, Yale School of Medicine
Jiamin LiuNational Clinical Research Center for Cardiovascular Diseases, National Health Commission Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Fang FengNational Clinical Research Center for Cardiovascular Diseases, National Health Commission Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Hao YangNational Clinical Research Center for Cardiovascular Diseases, National Health Commission Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Hongyu ZhaoYale University
Wade Schulz (CM4AI)Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, Yale School of Medicine
Harlan M KrumholzCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, Yale School of Medicine
Harlan M KrumholzCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, Yale School of Medicine
Xiangbin PanNational Clinical Research Center for Cardiovascular Diseases, National Health Commission Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Jing LiNational Clinical Research Center for Cardiovascular Diseases, National Health Commission Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Jing LiFuwai Hospital Chinese Academy of Medical Sciences
  • 1 - 19

Datasets

Release 1.2